Answers are grounded in this paper and cite their sources.
Systematic review reports high global prevalence of erectile dysfunction in men, highlighting age and comorbidities as key factors.
Introduction Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It is a common condition that significantly impacts quality of life and psychological well-being, and may signal underlying health issues. Globally, the burden of ED is large and rising – projections estimate that about 322 million men worldwide will experience ED by 2025. The prevalence of ED is influenced by multiple factors, notably age, chronic comorbidities (such as diabetes and cardiovascular disease), and lifestyle. Epidemiological studies across many countries have reported widely varying prevalence rates, largely due to differences in methodology and population characteristics. Objective Given the importance of understanding the global impact of ED, we conducted a systematic review of studies from 2010–2024 on ED prevalence in adult men (≥18 years). Following PRISMA guidelines, our aim was to synthesize how frequent ED is worldwide and identify general patterns (e.g. variation by age or region), providing insights for sexual health professionals and health authorities. Methods • Study Design: Systematic review performed according to PRISMA recommendations (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). We employed a comprehensive search strategy with clear inclusion/exclusion criteria and critical appraisal of studies. • Data Sources: Searched for publications (2010–2024) in multiple databases including Google Scholar, BVS (Virtual Health Library), SciELO, CAPES Periodicals, and institutional repositories. No language restrictions were applied; studies in any language were considered if they met inclusion criteria. Search terms combined descriptors for erectile dysfunction and prevalence (e.g., “erectile dysfunction prevalence”, “prevalência disfunção erétil”) adapted per database. • Inclusion/Exclusion Criteria: Included observational studies (primarily population-based surveys or cross-sectional studies) reporting ED prevalence in general male populations (age ≥18). Studies focusing exclusively on specific clinical subgroups (e.g., only men with a particular disease) were excluded unless they provided complementary context. Prevalence data from important subpopulations (such as diabetics) were noted for discussion, but the main focus remained on general male populations. • Study Selection: Two reviewers independently screened titles/abstracts and then full texts to identify eligible studies, resolving any disagreements by consensus. A PRISMA flow process was followed to document identification, screening, and inclusion (narratively described due to format constraints). • Data Extraction and Synthesis: From each included study, we extracted the reported prevalence of ED (point or period prevalence, as defined in the study), the operational definition/diagnostic criteria for ED (e.g., IIEF-5 questionnaire scores or self-reported erectile difficulties), sample size and age range, and any breakdown by ED severity (mild, moderate, severe). Given the expected heterogeneity across studies (different countries, methodologies, age distributions), we opted for a narrative (descriptive) synthesis rather than a formal meta-analysis. We identified common trends (such as increasing prevalence with age and regional patterns) and present data as descriptive ranges (with confidence intervals or absolute numbers when available). Results • Global Prevalence: ED is confirmed to be highly prevalent worldwide in the adult male population. Most studies report that approximately 20% to 50% of men experience some degree of ED. For example, a large standardized multinational survey (2015–2016) of men ≥18 across eight countries found ED prevalence (any difficulty in the last 6 months) ranging from 37.2% in Brazil to 48.6% in Italy, with most other countries (USA, UK, Spain, France, Germany, China) around 40–45%. These findings imply that when broad criteria are used (counting any erectile difficulty), roughly 2 in 5 men globally may be affected by ED. • Methodological Differences: Reported prevalence rates vary widely across studies due to different definitions and assessment methods. Stricter diagnostic criteria tend to yield lower percentages. For instance, a 2021 United States survey using the standardized IIEF-5 questionnaire found an ED prevalence of 24.2% (any degree) – roughly 1 in 4 men – which is lower than many international estimates that used more inclusive self-reported measures. Overall, prevalence figures in the literature range from under 1% to nearly 80%, reflecting differences in study populations (e.g., younger vs. older cohorts) and whether any ED vs. only moderate/severe ED is counted. Some surveys that counted even occasional erectile difficulty reported extremely high rates (e.g., ~79% in one Malaysian study), whereas studies focusing only on moderate-to-severe ED report much lower rates (often <15%). This underscores the need for caution when comparing studies with differing ED definitions. • Age-Related Trends: Age is the strongest determinant of ED prevalence. All data show a sharp rise in ED with increasing age. In general, fewer than 5–10% of men under 40 have ED, whereas over 50–60% of men above 70 are affected. For example, in the U.S. national survey, prevalence was only ~12–18% in men under 45, but climbed to 25% in ages 45–54, ~34% at 55–64, and about 48% in 65–74, reaching 52.2% in men ≥75 years. Consistently, more than half of elderly men experience ED, compared to only a small fraction of young men. As populations worldwide grow older, the absolute number of ED cases will rise correspondingly – a dynamic reflected in the projection of 300+ million global ED cases within the next decade. Conclusions • High and Rising Prevalence: Erectile dysfunction is highly prevalent worldwide, affecting an estimated 20–50% of adult men in the general population. This translates to a major public health issue, with projections exceeding 300 million affected men by 2025. The burden of ED will continue to grow as populations age, given the exponential increase in prevalence among older age groups. • Impact of Age and Comorbidities: Advancing age is the single greatest risk factor for ED – prevalence jumps from under 10% in younger men to over 50% in men above 70. In addition, chronic comorbidities significantly elevate risk: men with conditions like diabetes, cardiovascular disease, hypertension and other metabolic or urologic disorders have substantially higher ED rates. Notably, about two-thirds of men with diabetes worldwide experience ED. These patterns underscore that ED should be viewed in the context of overall health, as it often accompanies other medical issues. • Underdiagnosis and Need for Action: Despite its prevalence and impact on quality of life, ED remains underdiagnosed and under-discussed in clinical practice. There is a clear need for destigmatization of ED and better integration of sexual health into routine healthcare. Public health and clinical strategies should aim to reduce stigma, educate men that ED is a treatable medical condition (and not just an inevitable consequence of aging), and incorporate regular screening for erectile difficulties in at-risk populations. By doing so, healthcare providers can identify ED early, address any underlying conditions (e.g., diabetes or cardiac risk), and improve patients’ overall well-being. • Broader Implications: Our systematic review confirms that ED is not only a sexual health concern but also an important indicator of men’s general health status. Recognizing and treating ED has benefits beyond improving sexual function – it can lead to detection of other health problems and contributes to better quality of life for men and their partners. In summary, erectile dysfunction should be addressed with a multidisciplinary and global health approach, as emphasized by international sexual medicine societies, to ensure that more men receive appropriate evaluation, support, and treatment. Disclosure No
No takes yet. Share an insight, caveat, or question.
Sarnoski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: